The Clinical Landscape for Treatment-Resistant Depression Is Shifting
A recent feature in Psychiatric Times (April 2026) outlined the expanding toolkit clinicians are turning to when standard antidepressants fail. Among the approaches highlighted: ketamine and esketamine, alongside ECT, TMS, and newer pharmacological adjuncts. The piece underscores something the ketamine community has known for several years — that treatment-resistant depression (TRD), defined broadly as failing two or more adequate antidepressant trials, now has more credible intervention options than ever before.
For the estimated 30% of people with major depressive disorder who don't respond to first- or second-line treatments, that clinical recognition matters enormously. It signals not just evolving science, but a growing willingness within mainstream psychiatry to consider ketamine not as a last resort, but as a legitimate, evidence-backed option earlier in the care pathway.
Where Oral Ketamine Tablets Fit Into the TRD Picture
Most clinical discussions of ketamine in TRD center on IV infusions or intranasal esketamine (Spravato) — the two modalities with the most robust trial data. But for a growing number of patients, neither is practical. IV infusions require clinic visits every few days during induction, and Spravato's REMS program demands in-office monitoring for two hours per session. These are real barriers: cost, geography, scheduling, and the burden of repeated travel.
Oral ketamine tablets — typically compounded formulations of racemic ketamine — offer a different trade-off. Bioavailability is lower than IV (roughly 20–30% for oral versus near 100% for IV), meaning doses need to be calibrated accordingly. Absorption is slower and more variable, influenced by food intake and individual gastrointestinal factors. The result is a gentler onset curve with less acute dissociative intensity, which many patients actually prefer, particularly those managing anxiety alongside depression.
For TRD patients who have already explored or been excluded from infusion protocols, oral tablets represent a meaningful access bridge. When prescribed through a telehealth-enabled ketamine provider and taken at home under a structured protocol, tablets allow for consistent maintenance dosing without the logistical overhead of clinic-based care.
Tablets vs. Troches vs. Infusions: Understanding the Spectrum
It's worth clarifying the distinctions that often get blurred in patient conversations. Sublingual troches (lozenges dissolved under the tongue) achieve higher bioavailability than swallowed tablets — typically 30–40% — because they partially bypass first-pass liver metabolism. Patients are often instructed to hold troches in the mouth for 10–15 minutes before swallowing, maximizing mucosal absorption.
Oral tablets swallowed directly are metabolized more fully in the liver, converting ketamine to norketamine, a metabolite that carries its own antidepressant activity. Some researchers believe the norketamine pathway may actually contribute meaningfully to the sustained antidepressant effects seen with oral dosing — a hypothesis that distinguishes the oral route pharmacologically, not just logistically.
IV infusions, by contrast, deliver ketamine rapidly and at full bioavailability, producing the pronounced dissociative and psychedelic experiences that some patients find therapeutically meaningful and others find difficult to tolerate. The clinical outcomes data for IV ketamine in TRD is strong — but strong outcomes data also exists for oral and sublingual routes, particularly for maintenance. The framing that only IV ketamine is 'real' ketamine therapy is increasingly outdated.
Key Takeaway for Oral Ketamine Patients
If you're using ketamine tablets for treatment-resistant depression, lower bioavailability doesn't mean lower effectiveness — it means your prescriber needs to calibrate your dose appropriately for the oral route. Don't compare your milligram dose directly to what you read about IV protocols. Work with your provider to assess response over a consistent induction period, and flag any changes in mood, sleep, or side effects at each check-in.
What the Mainstream Recognition of TRD Options Means for Patients
When publications like Psychiatric Times frame ketamine as one of several legitimate, clinician-endorsed approaches to TRD — rather than an experimental outlier — it has practical downstream effects. Insurance coverage conversations become easier. Referring psychiatrists are more willing to co-manage patients. And patients themselves feel more empowered to advocate for access rather than accepting 'we've run out of options.'
For oral ketamine users specifically, this normalization matters in a few ways. First, it may accelerate the availability of compounded ketamine through more pharmacies and telehealth platforms as prescriber demand grows. Second, it reinforces the importance of structured protocols — proper induction schedules, integration support, and regular reassessment — rather than ad hoc use. The same clinical rigor being applied in infusion settings should follow the oral route.
Finally, as TRD management becomes more multidisciplinary, oral ketamine's role as a maintenance-phase tool becomes clearer. After stabilization via infusions or a structured tablet induction, many patients transition to lower-frequency oral dosing to sustain response. That maintenance layer — accessible, home-based, and lower-intensity — is where tablets genuinely shine, and where future outcomes research is likely to focus.
If you've been told you have treatment-resistant depression and haven't discussed oral ketamine as part of your care plan, it may be worth raising with your prescriber — or seeking a consultation with a provider who specializes in ketamine-based protocols.
Share